Background {#Sec1}
==========

Carcinoma of the uterine cervix is the most common gynecological cancer in developing countries. The most frequently reported metastases sites are lungs, bone, and liver \[[@CR1], [@CR2]\]. Skin metastases are extremely rare even in the late stages of disease; they have an incidence range from 0.1 to 2 % \[[@CR3], [@CR4]\]. The presence of metastatic disease in the skin is a strong predictive of poor prognosis, as skin metastases are usually associated with local or regional recurrence. The treatment is usually palliative with very poor outcomes. We report here the cases of two patients with locally advanced cervical cancer who developed cutaneous metastasis.

Case presentation {#Sec2}
=================

Case 1 {#Sec3}
------

Nine years ago a 63-year-old Moroccan woman was referred to our department with the complaint of postmenopausal bleeding and foul smelling vaginal discharge. A pelvic examination revealed a 4 cm cervical lesion extending to her upper vaginal wall with left parametrial extension. A biopsy indicated squamous cell carcinoma moderately differentiated and keratinizing of her cervix. Computed tomography of her chest, abdomen, and pelvis showed a cervical tumor of approximately 5 cm with hydroureteronephrosis. There was no evidence of distant metastasis. Consequently, she was staged as stage IIIB according to the International Federation of Gynecology and Obstetrics (FIGO) staging system. She received concurrent chemoradiation followed by low-dose brachytherapy.

Six months after finishing the treatment, she presented with multiple abdominal and thoracic subcutaneous nodules. A skin biopsy was performed and a diagnosis of metastatic squamous cell carcinoma was confirmed. She was then given palliative chemotherapy using a single drug protocol with carboplatin. However, the disease progressed, and she died before completing her fourth course of chemotherapy.

Case 2 {#Sec4}
------

A 48-year-old Moroccan woman presented to our radiotherapy department, 2 years ago, with a 6-month history of vaginal bleeding. On examination, a 5 cm cervical lesion extending to the upper third of her vagina with bilateral parametrial involvement was identified. A cervical biopsy confirmed squamous cell carcinoma that was well differentiated and keratinizing histology. Computed tomography of her chest, abdomen, and pelvis revealed a 5 cm cervical process extending up to the upper two-thirds of her vagina and the both parameters with multiple para-aortic and pelvic lymph nodes. There was no evidence of distant metastasis. She was staged as stage IIIB according to the FIGO staging system.

She was treated with concurrent chemotherapy and radiation. She received weekly cisplatin (40 mg/m^2^) and 46 Gy external beam radiation therapy to her pelvis in 23 fractions. Brachytherapy was planned before she reported the appearance of subcutaneous nodules on her arms, thighs, and chest wall (Fig. [1](#Fig1){ref-type="fig"}). A biopsy confirmed squamous cell carcinoma histology (Figs. [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"}).Fig. 1Cutaneous metastatic nodule in the upper extremityFig. 2Skin biopsy at 10× magnification (hematoxylin and eosin stain), showing carcinomatosis proliferation with spans and cordsFig. 3P63 immunohistochemistry performed on the skin biopsy which shows diffuse staining in the tumor cells (avidin-biotin at 40× magnification)

Computed tomography of her chest, abdomen, and pelvis, and a whole body bone scan revealed multiple lung, liver, and bone metastases. She died after two courses of palliative chemotherapy, 2 months after the appearance of the skin lesions.

Discussion {#Sec5}
==========

In Morocco, cervical cancer is the second most common cancer in the country and the third most common cause of death \[[@CR5]\]. Hematogenous spread is uncommon, presenting either in a recurrence setting or initially in advanced stages; it is often localized in the liver, lung, and bone, in order of decreasing frequency \[[@CR1], [@CR2], [@CR6]\].

The incidence of cutaneous metastasis from solid tumors ranges from 0.7 to 9 % \[[@CR1]\]. The most common solid tumors metastasizing to the skin in women include breast (60 to 69 %), gastrointestinal tract (9 %), lung, and ovary \[[@CR2]\]. Cutaneous metastases from carcinoma of the cervix are exceptional, even in the late stages of disease, with an incidence not exceeding 2 % \[[@CR3], [@CR4]\]. Imachi *et al*. \[[@CR7]\] in a review of 1190 patients with cervical cancer reported that 15 patients developed skin metastasis. The incidence of skin metastasis varied according to the initial tumor stage, it was 0.8 % in stage I, 1.2 % in stage II, 1.2 % in stage III, and 4.8 % in stage IV. The incidence of skin metastasis seemed to be higher in patients with adenocarcinoma and undifferentiated carcinoma than in patients with squamous cell carcinoma.

On macroscopic examination, three common patterns of skin metastasis, such as nodules, plaques, and inflammatory telangiectasic lesions, have been reported \[[@CR2], [@CR7]--[@CR9]\]. Lesions may be single or multiple. Our patients had multiple nodular lesions. The most common differential diagnoses include benign dermatitis, subcutaneous phycomycosis, plaque-like mycosis fungoides, and Kaposi's sarcoma \[[@CR10]\]. A pathological study establishes the diagnosis.

The abdominal wall and vulva are the most common sites for skin lesions, followed by the anterior chest wall \[[@CR2], [@CR11], [@CR12]\]. However, cases presenting at the scalp \[[@CR13], [@CR14]\], extremities \[[@CR15]\], umbilicus \[[@CR16]\], and face \[[@CR17]\] have been reported. In our cases, it was mainly localized in the chest and abdominal areas. The mechanism behind this type of metastases is not well established, the possible reason could be attributable to a retrograde spread of tumor secondary to lymphatic obstruction \[[@CR18]\].

To date, no effective treatment has been identified. Treatment is nearly always palliative, and consists of using radiation, chemotherapy, or surgery, either alone or in combination \[[@CR16], [@CR19]\]. Electrochemotherapy (ECT) can provide immediate clinical benefit in patients with advanced cutaneous and subcutaneous metastases \[[@CR20]\]. ECT combines the administration of a poorly permeant cytotoxic agent, such as bleomycin or cisplatin regardless of histological type, with the local application of electric pulses that induce reversible electroporation, thus improving drug diffusion into cells \[[@CR21], [@CR22]\]. ECT was introduced in 2006, demonstrating a high rate of efficacy and favorable toxicity profile in a European multicenter study on skin metastases from different tumor histotypes \[[@CR23]\]. In this study, the objective response rate on treated tumor nodules was 89.0 % with complete regression in 73.3 % of cases. For our patients who had multiple metastases, we opted for palliative chemotherapy.

Skin metastasis from cervical carcinoma occurs predominantly in cases of tumor recurrences, with metastasis developing up to 10 years after initial diagnosis and averaging less than 1 year \[[@CR24], [@CR25]\]. In the largest series \[[@CR7]\], the mean interval between the diagnosis of the primary tumor and skin metastasis was 16.9 months. Only two cases of cutaneous metastasis at initial presentation have been reported in the literature \[[@CR12], [@CR26]\]. In our report, both of the patients presented skin metastasis during the treatment or in the first months following treatment completion.

Prognosis in such cases is poor and is considered a sign for preterminal disease. The mean survival being 3 months and survival for more than 1 year seen in only 20 % of patients \[[@CR7], [@CR8], [@CR16]\]. The cases that we have reported are consistent with these findings.

Conclusions {#Sec6}
===========

Skin metastasis of cervical cancer remains extremely rare. Physicians should pay more attention to cutaneous lesions in patients with cervical cancer that can be the first sign of the disease, and should perform a biopsy whenever they are doubtful.

ECT

:   Electrochemotherapy

FIGO

:   International Federation of Gynecology and Obstetrics

Not applicable.

Funding {#FPar1}
=======

Not applicable.

Availability of data and materials {#FPar2}
==================================

Not applicable.

Authors' contributions {#FPar3}
======================

All the individuals listed as co-authors in this manuscript have participated in the research work and manuscript write-up in ways that conform to International Committee of Medical Journal Editors (ICMJE) authorship criteria. All authors read and approved the final manuscript.

Competing interests {#FPar4}
===================

The authors declare that they have no competing interests.

Consent for publication {#FPar5}
=======================

Written informed consent was obtained from the patients\' next-of-kin for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
